Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRONULIFE LvUCare
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
PRONULIFE LvUCare is a multi-strain probiotic and postbiotic combination developed by Glac Biotech. The formulation consists of three live bacterial strains—*Lactobacillus fermentum* TSF331, *Lactobacillus reuteri* TSR332, and *Lactobacillus plantarum* TSP05—combined with the postbiotic Totipro PE0401. It is primarily developed to manage metabolic-associated fatty liver disease (MAFLD), hyperuricemia, and elevated liver enzymes. The combination works by modulating the gut-liver axis to reduce systemic inflammation and metabolic markers, specifically lowering serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and uric acid. Clinical evidence from trial NCT06183801 demonstrated significant efficacy in improving liver function markers in patients with abnormal liver function and elevated uric acid.
- Brand names
- PRONULIFE LvUCare
- Other names
- lactobacillus fermentum TSF331 + lactobacillus reuteri TSR332 + lactobacillus plantarum TSP05 + postbiotics PE0401PRONULIFE LvU CareLvUCare
Beyond the preview
Go deeper on PRONULIFE LvUCare.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRONULIFE LvUCare.